our current active studies

ARISE Clinical Trial, Phase 3

ROSSINI Clinical Trial, Observational

Elevate-PD Clinical Trial, Phase 4

Sponsor: Cerevance
Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Complications
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424 or 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.

Elevate-PD Clinical Trial, Phase 4

ROSSINI Clinical Trial, Observational

Elevate-PD Clinical Trial, Phase 4

Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

ROSSINI Clinical Trial, Observational

Sponsor: AbbVie
The purpose of this study is to evaluate how effective ABBV-951 is in treating adult participants with advanced PD in real world setting.
ABBV-951 (foslevodopa/foscarbidopa) is an approved drug for the treatment of Parkinson's Disease. The main ROSSINI study will have approximately 450 adult participants with PD (300 participants new to ABBV-951, up to 150 participants transitioning from open-label extension study) will be enrolled across approximately 60 sites. Decision to treat with ABBV-951 (or continue the treatment in Cohort B) will be made by the doctor prior to any decision to approach the participant to participate in this study. There will be a sub-study that will enroll 40 naïve participants who initiated Foslevodopa/Foscarbidopa treatment for the first time (Cohort A of the ROSSINI parent study only) from 6 to 15 centers in the United States, Germany and Spain.
All participants will receive subcutaneous infusion of ABBV-951 for approximately 3 years.
Participants will attend regular clinic visits during the course of the study. The effect of the treatment will be checked by medical assessments, and completing questionnaires.

ONAPGO Clinical Trial, Observational

Syn-Q REM Sleep/PD Testing Clinical Trial, Observational

ROSSINI Clinical Trial, Observational

Sponsor: Supernus
Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease
This observational study includes an Enrollment Day (participants enrolled any time between their prescription for the infusion and ONAPGO initiation); a Baseline Period (prior to ONAPGO initiation which includes in-home education on the use of ONAPGO by the Clinical Nurse Navigator [CNN] according to standard practice for patients with PD-prescribed ONAPGO); Dose Initiation, Titration, and Optimization per Prescription Periods; a Maintenance Period; Maintenance CNN standard of care visits; and an End-of-Study (EOS)/Discontinuation Visit.

PDGENE-PF Testing Clinical Trial

Syn-Q REM Sleep/PD Testing Clinical Trial, Observational

Sponsor: Parkinson's Foundation
General Summary: Genetic study where they analyze the genetics in the participant's blood to see if there are any mutations related to Parkinson’s
Target Population: Parkinson’s patients as well as family members who may be at risk for PD

Syn-Q REM Sleep/PD Testing Clinical Trial, Observational

Sponsor: CND Life Sciences
Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
This is a prospective, longitudinal study involving 75 Parkinson's disease patients and 25 patients with REM Behavior Disorder. Each participant will undergo a baseline evaluation followed by follow-ups every six months over an 18-month period. The evaluations will include clinical assessments, neurologic exams, and skin biopsies from three locations. Data will be collected on disease progression and the amount of P-SYN in cutaneous nerve fibers.

VIMA Clinical Trial, Observational

TrueBinding Clinical Trial, Phase 2

VIMA Clinical Trial, Observational

Sponsor: Vima Therapeutics
An Observational Study of Individuals With Isolated Dystonia
This is an observational study in individuals with isolated (or primary) dystonia that involves more than one body region. The purpose of the study is to collect detailed information to help your physician and other researchers understand how dystonia impacts your and other patients' lives and how the disease changes over time. The study may also help researchers better understand the clinical scales that are commonly used to evaluate dystonia symptoms and how they affect various areas of life such as well-being, pain, relationships and social interactions, and progress over time. Because this is an observational study, you will not receive any interventional treatment in the study.
The primary goal of this observational study is to further characterize and quantify disease severity and impact (including change over time) in individuals with either segmental, multifocal, or generalized dystonia in a structured manner, utilizing and comparing various well-known scales. In addition, medication history and any intercurrent events related to the participant's health (such as, but not limited to, hospitalizations, new diagnoses, etc.) will be captured. This study will provide standardized data to support planned future interventional clinical studies in this patient population and will provide a greater understanding of the population under study and the performance of clinical ratings scales.

NEULARK Clinical Trial, Phase 2

TrueBinding Clinical Trial, Phase 2

VIMA Clinical Trial, Observational

Sponsor: Neuron23 Inc.
General Summary: The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway
Participants will: Take NEU-411 or placebo every day for 52 weeks
NEU-411-PD201 is a Phase 2, randomized, placebo-controlled, proof-of-concept study in participants with early Parkinson's Disease (PD) who have LRRK2-driven PD as measured by an investigational companion diagnostic genetic test (CDx). The study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NEU-411, an orally-administered, potent, selective, bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity as compared to placebo.
After participants are screened for inclusion in the study, approximately 150 participants will be randomized in a 1:1 allocation ratio to NEU-411 30 mg once per day or placebo for a 52-week treatment period. A safety follow-up visit will occur 2 weeks after the last treatment visit.

TrueBinding Clinical Trial, Phase 2

Sponsor: TrueBinding, Inc.
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of TB006 in Participants With Parkinson's Disease
The primary objectives of this study are to assess the efficacy of TB006 in improving motor function and to assess the safety of TB006 in participants with Parkinson's Disease (PD).

our current active studies

ARISE Clinical Trial, Phase 3

ROSSINI Clinical Trial, Observational

Elevate-PD Clinical Trial, Phase 4

Elevate-PD Clinical Trial, Phase 4

ROSSINI Clinical Trial, Observational

Elevate-PD Clinical Trial, Phase 4

ROSSINI Clinical Trial, Observational

ROSSINI Clinical Trial, Observational

ROSSINI Clinical Trial, Observational

ONAPGO Clinical Trial, Observational

Syn-Q REM Sleep/PD Testing Clinical Trial, Observational

ROSSINI Clinical Trial, Observational

PDGENE-PF Testing Clinical Trial

Syn-Q REM Sleep/PD Testing Clinical Trial, Observational

Syn-Q REM Sleep/PD Testing Clinical Trial, Observational

Syn-Q REM Sleep/PD Testing Clinical Trial, Observational

Syn-Q REM Sleep/PD Testing Clinical Trial, Observational

Syn-Q REM Sleep/PD Testing Clinical Trial, Observational

VIMA Clinical Trial, Observational

TrueBinding Clinical Trial, Phase 2

VIMA Clinical Trial, Observational

NEULARK Clinical Trial, Phase 2

TrueBinding Clinical Trial, Phase 2

VIMA Clinical Trial, Observational

TrueBinding Clinical Trial, Phase 2

TrueBinding Clinical Trial, Phase 2

TrueBinding Clinical Trial, Phase 2

If you or someone you know is interested in participating in any of our studies and wants to know more please fill this out